← SynDRA
GLECAPREVIR
SynDRA canonical compound SYN0038283 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | NS3/4A |
|---|
| Mechanism of action | serine protease inhibitor |
|---|
| Indication | hepatitis C |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- serine protease inhibitor
Drug classes
- Cytochrome P450 1A2 Inhibitors
- HCV NS3/4A Protease Inhibitors
- Hepatitis C Virus NS3/4A Protease Inhibitor
- P-Glycoprotein Inhibitors
- Organic Anion Transporting Polypeptide 1B1 Inhibitors
- Organic Anion Transporting Polypeptide 1B3 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Cytochrome P450 3A Inhibitors
- UGT1A1 Inhibitors
ATC classes
Cross-references
Synonyms
- ABT-493
- A-1282576.0
- A-1282576
- A-12825760
- Glecaprevir component of mavyret
- ABT 493
- Maviret
- K6BUU8J72P
- glecaprevirum
- RefChem:663069
- DTXCID101513512
- Glecaprevir [USAN]
- UNII-K6BUU8J72P
- O31
- GLECAPREVIR [MI]
- GLECAPREVIR [INN]
- Glecaprevir (USAN/INN)
- ABT-493(Glecaprevir)?
- GLECAPREVIR [WHO-DD]
- SCHEMBL883097
- ABT493
- orb1302067
- SCHEMBL29368105
- GTPL11267
- GLECAPREVIR [ORANGE BOOK]
- EX-A1940
- MAVYRET COMPONENT GLECAPREVIR
- BDBM50573891
- s5720
- CS-8098
- AC-33419
- HY-17634
- NS00133774
- D10814
- D84121
- F836983
- غليكابريفير
- گلکاپرویر
Reported adverse events
- Angioedema
- Fatigue
- Headache
- Nausea
Look up GLECAPREVIR in the interactive SynDRA portal →